|Articles|September 26, 2014

EFPIA Promises Stronger Ties with China

The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”. Federation delegates are this week concluding a visit to Beijing to establish “a better understanding of the numerous healthcare reforms underway in China … and explore closer paths of cooperation in global drug development between China and Europe”.

The EFPIA delegation included global CEOs, EFPIA Director General Richard Bergstrom, and EFPIA President and Sanofi CEO, Chris Viehbacher. The delegates have taken part in a series of events in Beijing, including a conference on Translational Medicine and a workshop on Transparency and Good Governance.

Viehbacher commented: “EFPIA is committed to fostering productive relations with China… The research-based pharmaceutical industry is a global industry, and this visit marks an important milestone in fostering understanding between international health care leaders and promoting awareness about the advancements taking place in China’s life sciences sector.”


Related to this article

Pharmaceutical Executive Daily
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.